Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 87

1.

Correction to: Epigenetic regulation of L1CAM in endometrial carcinoma: comparison to cancer-testis (CT-X) antigens.

Schirmer U, Fiegl H, Pfeifer M, Zeimet AG, Müller-Holzner E, Bode PK, Tischler V, Altevogt P.

BMC Cancer. 2018 Oct 29;18(1):1047. doi: 10.1186/s12885-018-4928-y.

2.

Inborn-like errors of metabolism are determinants of breast cancer risk, clinical response and survival: a study of human biochemical individuality.

da Silva I, da Costa Vieira R, Stella C, Loturco E, Carvalho AL, Veo C, Neto C, Silva SM, D'Amora P, Salzgeber M, Matos D, Silva CR, Oliveira JR, Rabelo I, Yamakawa P, Maciel R, Biscolla R, Chiamolera M, Fraietta R, Reis F, Mori M, Marchioni D, Carioca A, Maciel G, Tomioka R, Baracat E, Silva C, Granato C, Diaz R, Scarpellini B, Egle D, Fiegl H, Himmel I, Troi C, Nagourney R.

Oncotarget. 2018 Aug 3;9(60):31664-31681. doi: 10.18632/oncotarget.25839. eCollection 2018 Aug 3.

3.

BRCA1 and BRCA2 mRNA-expression prove to be of clinical impact in ovarian cancer.

Tsibulak I, Wieser V, Degasper C, Shivalingaiah G, Wenzel S, Sprung S, Lax SF, Marth C, Fiegl H, Zeimet AG.

Br J Cancer. 2018 Sep;119(6):683-692. doi: 10.1038/s41416-018-0217-4. Epub 2018 Aug 15.

PMID:
30111871
4.

Evaluation of Vav3.1 as prognostic marker in endometrial cancer.

Boesch M, Sopper S, Marth C, Fiegl H, Wiedemair A, Rössler J, Hatina J, Wolf D, Reimer D, Zeimet AG.

J Cancer Res Clin Oncol. 2018 Oct;144(10):2067-2076. doi: 10.1007/s00432-018-2725-2. Epub 2018 Aug 6.

5.

BRCA1/2 and TP53 mutation status associates with PD-1 and PD-L1 expression in ovarian cancer.

Wieser V, Gaugg I, Fleischer M, Shivalingaiah G, Wenzel S, Sprung S, Lax SF, Zeimet AG, Fiegl H, Marth C.

Oncotarget. 2018 Apr 3;9(25):17501-17511. doi: 10.18632/oncotarget.24770. eCollection 2018 Apr 3.

6.

Development of a novel prognostic score for breast cancer patients using mRNA expression of CHAC1.

Jahn B, Arvandi M, Rochau U, Fiegl H, Goebel G, Marth C, Siebert U.

J Comp Eff Res. 2017 Oct;6(7):563-574. doi: 10.2217/cer-2017-0015. Epub 2017 Sep 19.

PMID:
29091014
7.

FOXO3-mediated chemo-protection in high-stage neuroblastoma depends on wild-type TP53 and SESN3.

Rupp M, Hagenbuchner J, Rass B, Fiegl H, Kiechl-Kohlendorfer U, Obexer P, Ausserlechner MJ.

Oncogene. 2017 Nov 2;36(44):6190-6203. doi: 10.1038/onc.2017.288. Epub 2017 Sep 4.

8.

Methylome analysis of extreme chemoresponsive patients identifies novel markers of platinum sensitivity in high-grade serous ovarian cancer.

Tomar T, Alkema NG, Schreuder L, Meersma GJ, de Meyer T, van Criekinge W, Klip HG, Fiegl H, van Nieuwenhuysen E, Vergote I, Widschwendter M, Schuuring E, van der Zee AGJ, de Jong S, Wisman GBA.

BMC Med. 2017 Jun 23;15(1):116. doi: 10.1186/s12916-017-0870-0.

9.

KCNJ3 is a new independent prognostic marker for estrogen receptor positive breast cancer patients.

Kammerer S, Sokolowski A, Hackl H, Platzer D, Jahn SW, El-Heliebi A, Schwarzenbacher D, Stiegelbauer V, Pichler M, Rezania S, Fiegl H, Peintinger F, Regitnig P, Hoefler G, Schreibmayer W, Bauernhofer T.

Oncotarget. 2016 Dec 20;7(51):84705-84717. doi: 10.18632/oncotarget.13224.

10.

Evaluating L1CAM expression in human endometrial cancer using qRT-PCR.

Notaro S, Reimer D, Duggan-Peer M, Fiegl H, Wiedermair A, Rössler J, Altevogt P, Marth C, Zeimet AG.

Oncotarget. 2016 Jun 28;7(26):40221-40232. doi: 10.18632/oncotarget.9574.

11.
12.

Application of interferon modulators to overcome partial resistance of human ovarian cancers to VSV-GP oncolytic viral therapy.

Dold C, Rodriguez Urbiola C, Wollmann G, Egerer L, Muik A, Bellmann L, Fiegl H, Marth C, Kimpel J, von Laer D.

Mol Ther Oncolytics. 2016 Sep 28;3:16021. eCollection 2016.

13.

Evaluation of folate receptor 1 (FOLR1) mRNA expression, its specific promoter methylation and global DNA hypomethylation in type I and type II ovarian cancers.

Notaro S, Reimer D, Fiegl H, Schmid G, Wiedemair A, Rössler J, Marth C, Zeimet AG.

BMC Cancer. 2016 Aug 2;16:589. doi: 10.1186/s12885-016-2637-y.

14.

High prevalence of side population in human cancer cell lines.

Boesch M, Zeimet AG, Fiegl H, Wolf B, Huber J, Klocker H, Gastl G, Sopper S, Wolf D.

Oncoscience. 2016 Apr 10;3(3-4):85-87. doi: 10.18632/oncoscience.300. eCollection 2016.

15.

Clinical impact of L1CAM expression measured on the transcriptome level in ovarian cancer.

Abdel Azim S, Duggan-Peer M, Sprung S, Reimer D, Fiegl H, Soleiman A, Marth C, Zeimet AG.

Oncotarget. 2016 Jun 14;7(24):37205-37214. doi: 10.18632/oncotarget.9291.

16.

Expression and promotor hypermethylation of miR-34a in the various histological subtypes of ovarian cancer.

Schmid G, Notaro S, Reimer D, Abdel-Azim S, Duggan-Peer M, Holly J, Fiegl H, Rössler J, Wiedemair A, Concin N, Altevogt P, Marth C, Zeimet AG.

BMC Cancer. 2016 Feb 15;16:102. doi: 10.1186/s12885-016-2135-2.

17.

HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer.

Teschendorff AE, Lee SH, Jones A, Fiegl H, Kalwa M, Wagner W, Chindera K, Evans I, Dubeau L, Orjalo A, Horlings HM, Niederreiter L, Kaser A, Yang W, Goode EL, Fridley BL, Jenner RG, Berns EM, Wik E, Salvesen HB, Wisman GB, van der Zee AG, Davidson B, Trope CG, Lambrechts S, Vergote I, Calvert H, Jacobs IJ, Widschwendter M.

Genome Med. 2015 Oct 24;7:108. doi: 10.1186/s13073-015-0233-4.

18.

Detection of soluble EpCAM (sEpCAM) in malignant ascites predicts poor overall survival in patients treated with catumaxomab.

Seeber A, Braicu I, Untergasser G, Nassir M, Fong D, Botta L, Gastl G, Fiegl H, Zeimet A, Sehouli J, Spizzo G.

Oncotarget. 2015 Sep 22;6(28):25017-23. doi: 10.18632/oncotarget.4496.

19.

High prevalence of BRCA1 stop mutation c.4183C>T in the Tyrolean population: implications for genetic testing.

Pölsler L, Fiegl H, Wimmer K, Oberaigner W, Amberger A, Traunfellner P, Morscher RJ, Weber I, Fauth C, Wernstedt A, Sperner-Unterweger B, Oberguggenberger A, Hubalek M, Marth C, Zschocke J.

Eur J Hum Genet. 2016 Feb;24(2):258-62. doi: 10.1038/ejhg.2015.108. Epub 2015 May 27.

20.

Serum HE4 detects recurrent endometrial cancer in patients undergoing routine clinical surveillance.

Brennan DJ, Hackethal A, Mann KP, Mutz-Dehbalaie I, Fiegl H, Marth C, Obermair A.

BMC Cancer. 2015 Feb 6;15:33. doi: 10.1186/s12885-015-1028-0.

21.

A concept of a MIABIS based register of biosample collections at the Medical University of Innsbruck.

Hofer P, Fiegl H, Angerer J, Mueller-Holzner E, Chamson M, Klocker H, Steiner E, Hauffe H, Zschocke J, Goebel G.

Stud Health Technol Inform. 2014;205:293-7.

PMID:
25160193
22.

miR-21-3p is a positive regulator of L1CAM in several human carcinomas.

Doberstein K, Bretz NP, Schirmer U, Fiegl H, Blaheta R, Breunig C, Müller-Holzner E, Reimer D, Zeimet AG, Altevogt P.

Cancer Lett. 2014 Nov 28;354(2):455-66. doi: 10.1016/j.canlet.2014.08.020. Epub 2014 Aug 19.

PMID:
25149066
23.

Epigenetics in the perioperative period.

Lirk P, Fiegl H, Weber NC, Hollmann MW.

Br J Pharmacol. 2015 Jun;172(11):2748-55. doi: 10.1111/bph.12865. Epub 2015 Apr 27. Review.

24.

Association of TNFRSF10D DNA-methylation with the survival of melanoma patients.

Ratzinger G, Mitteregger S, Wolf B, Berger R, Zelger B, Weinlich G, Fritsch P, Goebel G, Fiegl H.

Int J Mol Sci. 2014 Jul 7;15(7):11984-95. doi: 10.3390/ijms150711984.

25.

Lidocaine and ropivacaine, but not bupivacaine, demethylate deoxyribonucleic acid in breast cancer cells in vitro.

Lirk P, Hollmann MW, Fleischer M, Weber NC, Fiegl H.

Br J Anaesth. 2014 Jul;113 Suppl 1:i32-8. doi: 10.1093/bja/aeu201. Epub 2014 Jun 19.

26.

In situ proliferation contributes to accumulation of tumor-associated macrophages in spontaneous mammary tumors.

Tymoszuk P, Evens H, Marzola V, Wachowicz K, Wasmer MH, Datta S, Müller-Holzner E, Fiegl H, Böck G, van Rooijen N, Theurl I, Doppler W.

Eur J Immunol. 2014 Aug;44(8):2247-62. doi: 10.1002/eji.201344304. Epub 2014 Jun 16.

27.

High STAT1 mRNA levels but not its tyrosine phosphorylation are associated with macrophage infiltration and bad prognosis in breast cancer.

Tymoszuk P, Charoentong P, Hackl H, Spilka R, Müller-Holzner E, Trajanoski Z, Obrist P, Revillion F, Peyrat JP, Fiegl H, Doppler W.

BMC Cancer. 2014 Apr 12;14:257. doi: 10.1186/1471-2407-14-257.

28.

Role of miR-34a as a suppressor of L1CAM in endometrial carcinoma.

Schirmer U, Doberstein K, Rupp AK, Bretz NP, Wuttig D, Kiefel H, Breunig C, Fiegl H, Müller-Holzner E, Zeillinger R, Schuster E, Zeimet AG, Sültmann H, Altevogt P.

Oncotarget. 2014 Jan 30;5(2):462-72.

29.

Role of DNA methylation and epigenetic silencing of HAND2 in endometrial cancer development.

Jones A, Teschendorff AE, Li Q, Hayward JD, Kannan A, Mould T, West J, Zikan M, Cibula D, Fiegl H, Lee SH, Wik E, Hadwin R, Arora R, Lemech C, Turunen H, Pakarinen P, Jacobs IJ, Salvesen HB, Bagchi MK, Bagchi IC, Widschwendter M.

PLoS Med. 2013 Nov;10(11):e1001551. doi: 10.1371/journal.pmed.1001551. Epub 2013 Nov 12.

30.

GALR1 methylation in vaginal swabs is highly accurate in identifying women with endometrial cancer.

Doufekas K, Hadwin R, Kandimalla R, Jones A, Mould T, Crowe S, Olaitan A, Macdonald N, Fiegl H, Wik E, Salvesen HB, Widschwendter M.

Int J Gynecol Cancer. 2013 Jul;23(6):1050-5. doi: 10.1097/IGC.0b013e3182959103.

PMID:
23727823
31.

Long non-coding RNAs as targets for cytosine methylation.

Amort T, Soulière MF, Wille A, Jia XY, Fiegl H, Wörle H, Micura R, Lusser A.

RNA Biol. 2013 Jun;10(6):1003-8. doi: 10.4161/rna.24454. Epub 2013 Apr 1.

32.

Epigenetic regulation of L1CAM in endometrial carcinoma: comparison to cancer-testis (CT-X) antigens.

Schirmer U, Fiegl H, Pfeifer M, Zeimet AG, Müller-Holzner E, Bode PK, Tischler V, Altevogt P.

BMC Cancer. 2013 Mar 26;13:156. doi: 10.1186/1471-2407-13-156. Erratum in: BMC Cancer. 2018 Oct 29;18(1):1047.

33.

Polymorphisms in the gene regions of the adaptor complex LAMTOR2/LAMTOR3 and their association with breast cancer risk.

De Araujo ME, Erhart G, Buck K, Müller-Holzner E, Hubalek M, Fiegl H, Campa D, Canzian F, Eilber U, Chang-Claude J, Coassin S, Haun M, Kedenko L, Paulweber B, Reitsamer R, Himmel I, Flesch-Janys D, Lamina C, Kronenberg F, Huber LA, Kloss-Brandstätter A.

PLoS One. 2013;8(1):e53768. doi: 10.1371/journal.pone.0053768. Epub 2013 Jan 16.

34.

Clinical relevance of CDH1 and CDH13 DNA-methylation in serum of cervical cancer patients.

Abudukadeer A, Bakry R, Goebel G, Mutz-Dehbalaie I, Widschwendter A, Bonn GK, Fiegl H.

Int J Mol Sci. 2012;13(7):8353-63. doi: 10.3390/ijms13078353. Epub 2012 Jul 5.

35.

Ovarian cancer stem cells.

Zeimet AG, Reimer D, Sopper S, Boesch M, Martowicz A, Roessler J, Wiedemair AM, Rumpold H, Untergasser G, Concin N, Hofstetter G, Muller-Holzner E, Fiegl H, Marth C, Wolf D, Pesta M, Hatina J.

Neoplasma. 2012;59(6):747-55. doi: 10.4149/neo_2012_094. Review.

PMID:
22862176
36.

Tamoxifen-induced epigenetic silencing of oestrogen-regulated genes in anti-hormone resistant breast cancer.

Stone A, Valdés-Mora F, Gee JM, Farrow L, McClelland RA, Fiegl H, Dutkowski C, McCloy RA, Sutherland RL, Musgrove EA, Nicholson RI.

PLoS One. 2012;7(7):e40466. doi: 10.1371/journal.pone.0040466. Epub 2012 Jul 10.

37.

Lidocaine time- and dose-dependently demethylates deoxyribonucleic acid in breast cancer cell lines in vitro.

Lirk P, Berger R, Hollmann MW, Fiegl H.

Br J Anaesth. 2012 Aug;109(2):200-7. doi: 10.1093/bja/aes128. Epub 2012 Apr 27. Erratum in: Br J Anaesth. 2013 Jan;110(1):165.

38.

HE4 is an independent prognostic marker in endometrial cancer patients.

Mutz-Dehbalaie I, Egle D, Fessler S, Hubalek M, Fiegl H, Marth C, Widschwendter A.

Gynecol Oncol. 2012 Aug;126(2):186-91. doi: 10.1016/j.ygyno.2012.04.022. Epub 2012 Apr 21.

PMID:
22525819
39.

FOXO3/FKHRL1 is activated by 5-aza-2-deoxycytidine and induces silenced caspase-8 in neuroblastoma.

Geiger K, Hagenbuchner J, Rupp M, Fiegl H, Sergi C, Meister B, Kiechl-Kohlendorfer U, Müller T, Ausserlechner MJ, Obexer P.

Mol Biol Cell. 2012 Jun;23(11):2226-34. doi: 10.1091/mbc.E11-06-0535. Epub 2012 Apr 4.

40.

Epigenetic variability in cells of normal cytology is associated with the risk of future morphological transformation.

Teschendorff AE, Jones A, Fiegl H, Sargent A, Zhuang JJ, Kitchener HC, Widschwendter M.

Genome Med. 2012 Mar 27;4(3):24.

41.

The dynamics and prognostic potential of DNA methylation changes at stem cell gene loci in women's cancer.

Zhuang J, Jones A, Lee SH, Ng E, Fiegl H, Zikan M, Cibula D, Sargent A, Salvesen HB, Jacobs IJ, Kitchener HC, Teschendorff AE, Widschwendter M.

PLoS Genet. 2012 Feb;8(2):e1002517. doi: 10.1371/journal.pgen.1002517. Epub 2012 Feb 9. Erratum in: PLoS Genet. 2012 Mar;8(3). doi: 10.1371/annotation/35f168f3-c509-4b4f-b245-f6682325838e.

42.

Mutual antagonism of TGF-beta and Interleukin-2 in cell survival and lineage commitment of induced regulatory T cells.

Tischner D, Wiegers GJ, Fiegl H, Drach M, Villunger A.

Cell Death Differ. 2012 Aug;19(8):1277-87. doi: 10.1038/cdd.2012.7. Epub 2012 Feb 10.

43.

The N-terminally truncated p53 isoform Δ40p53 influences prognosis in mucinous ovarian cancer.

Hofstetter G, Berger A, Berger R, Zorić A, Braicu EI, Reimer D, Fiegl H, Marth C, Zeimet AG, Ulmer H, Moll U, Zeillinger R, Concin N.

Int J Gynecol Cancer. 2012 Mar;22(3):372-9. doi: 10.1097/IGC.0b013e31823ca031.

PMID:
22246403
44.

Elevated mRNA expression of CHAC1 splicing variants is associated with poor outcome for breast and ovarian cancer patients.

Goebel G, Berger R, Strasak AM, Egle D, Müller-Holzner E, Schmidt S, Rainer J, Presul E, Parson W, Lang S, Jones A, Widschwendter M, Fiegl H.

Br J Cancer. 2012 Jan 3;106(1):189-98. doi: 10.1038/bjc.2011.510. Epub 2011 Nov 22.

45.

The Impact of Sample Storage Time on Estimates of Association in Biomarker Discovery Studies.

Kugler KG, Hackl WO, Mueller LA, Fiegl H, Graber A, Pfeiffer RM.

J Clin Bioinforma. 2011 Mar 8;1. pii: 9.

46.

Regulation of transcription factor E2F3a and its clinical relevance in ovarian cancer.

Reimer D, Hubalek M, Kiefel H, Riedle S, Skvortsov S, Erdel M, Hofstetter G, Concin N, Fiegl H, Müller-Holzner E, Marth C, Altevogt P, Zeimet AG.

Oncogene. 2011 Sep 22;30(38):4038-49. doi: 10.1038/onc.2011.119. Epub 2011 Apr 25.

PMID:
21516127
47.

DNA ploidy, nuclear size, proliferation index and DNA-hypomethylation in ovarian cancer.

Zeimet AG, Fiegl H, Goebel G, Kopp F, Allasia C, Reimer D, Steppan I, Mueller-Holzner E, Ehrlich M, Marth C.

Gynecol Oncol. 2011 Apr;121(1):24-31. doi: 10.1016/j.ygyno.2010.12.332. Epub 2011 Jan 20.

48.

Urinary neopterin does not reflect the local antitumor immune milieu in ovarian cancer.

Zeimet AG, Reimer D, Schwentner L, Fuchs D, Wolf D, Fuith LC, Fiegl H, Doppler W, Concin N, Daxenbichler G, Marth C.

Cancer Immunol Immunother. 2010 Dec;59(12):1813-23. doi: 10.1007/s00262-010-0907-0. Epub 2010 Aug 18.

PMID:
20717669
49.

E2F3a is critically involved in epidermal growth factor receptor-directed proliferation in ovarian cancer.

Reimer D, Hubalek M, Riedle S, Skvortsov S, Erdel M, Concin N, Fiegl H, Müller-Holzner E, Marth C, Illmensee K, Altevogt P, Zeimet AG.

Cancer Res. 2010 Jun 1;70(11):4613-23. doi: 10.1158/0008-5472.CAN-09-3551. Epub 2010 May 11.

50.

Toll-like receptor 9 expression in breast and ovarian cancer is associated with poorly differentiated tumors.

Berger R, Fiegl H, Goebel G, Obexer P, Ausserlechner M, Doppler W, Hauser-Kronberger C, Reitsamer R, Egle D, Reimer D, Müller-Holzner E, Jones A, Widschwendter M.

Cancer Sci. 2010 Apr;101(4):1059-66. doi: 10.1111/j.1349-7006.2010.01491.x. Epub 2010 Jan 12.

Supplemental Content

Support Center